{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:07:31Z","timestamp":1793844451266,"version":"4.6.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011151","name":"American Academy of Ophthalmology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","aaojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ophtha.2024.09.003","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T22:12:14Z","timestamp":1729635134000},"page":"343-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Therapies for Central Serous Chorioretinopathy"],"prefix":"10.1016","volume":"132","author":[{"given":"Leo A.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen G.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Y.","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieraj","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina J.","family":"Flaxel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriji","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2024.09.003_bib1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","article-title":"Central serous chorioretinopathy","volume":"86","author":"Wang","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100973","article-title":"Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders","volume":"86","author":"Spaide","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2024.09.003_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/02713680903428306","article-title":"Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study","volume":"35","author":"Artunay","year":"2010","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2024.09.003_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3341\/kjo.2010.24.3.155","article-title":"The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy","volume":"24","author":"Lim","year":"2010","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib5","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s10384-012-0162-3","article-title":"Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy","volume":"56","author":"Semeraro","year":"2012","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5507\/bp.2013.015","article-title":"Treatment of central serous chorioretinopathy with beta-blocker metipranolol","volume":"159","author":"Chrapek","year":"2015","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.ophtha.2024.09.003_bib7","first-page":"99","article-title":"The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy","volume":"17","author":"Rahbani-Nobar","year":"2011","journal-title":"Mol Vis"},{"key":"10.1016\/j.ophtha.2024.09.003_bib8","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00417-016-3315-0","article-title":"Clinical efficiency of Helicobacter pylori eradication in the treatment of patients with acute central serous chorioretinopathy","volume":"254","author":"Zavoloka","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2415-12-20","article-title":"High-dose antioxidants for central serous chorioretinopathy; the randomized placebo-controlled study","volume":"12","author":"Ratanasukon","year":"2012","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000455807","article-title":"A\u00a0multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy","volume":"237","author":"Shinojima","year":"2017","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2024.09.003_bib12","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ophtha.2008.04.014","article-title":"Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial","volume":"115","author":"Chan","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.09.003_bib13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/jamaophthalmol.2014.5312","article-title":"A\u00a050% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial","volume":"133","author":"Zhao","year":"2015","journal-title":"JAMA. Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib14","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1097\/FTD.0b013e31820beb02","article-title":"Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial","volume":"31","author":"Wu","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2024.09.003_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0002-9394(83)90265-9","article-title":"Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy","volume":"95","author":"Robertson","year":"1983","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2415-4-15","article-title":"Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial [ISRCTN84128484]","volume":"4","author":"Verma","year":"2004","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bjo.2009.178327","article-title":"Selective retina therapy for acute central serous chorioretinopathy","volume":"95","author":"Klatt","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/IAE.0b013e3182670fa3","article-title":"Improvement in visual acuity and contrast sensitivity in patients with central serous chorioretinopathy after macular subthreshold laser therapy","volume":"33","author":"Behnia","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2024.09.003_bib19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3928\/23258160-20170630-07","article-title":"Early focal laser photocoagulation in acute central serous chorioretinopathy: a prospective, randomized study","volume":"48","author":"Ambiya","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2024.09.003_bib20","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","article-title":"Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The PLACE Trial","volume":"125","author":"van Dijk","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.09.003_bib21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ajo.2010.12.007","article-title":"Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy","volume":"151","author":"Reibaldi","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3928\/23258160-20150909-08","article-title":"Randomized clinical trial to compare micropulse photocoagulation versus half-dose verteporfin photodynamic therapy in the treatment of central serous chorioretinopathy","volume":"46","author":"Kretz","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2024.09.003_bib22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/IAE.0000000000001138","article-title":"Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy","volume":"37","author":"Cheng","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2024.09.003_bib24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00417-017-3626-9","article-title":"Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy","volume":"255","author":"Russo","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/bjophthalmol-2020-316076","article-title":"Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy","volume":"105","author":"Ho","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000345495","article-title":"Intravitreal ranibizumab for acute central serous chorioretinopathy","volume":"229","author":"Kim","year":"2013","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2024.09.003_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/jop.2012.0072","article-title":"The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy","volume":"29","author":"Aydin","year":"2013","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2024.09.003_bib28","first-page":"3375","article-title":"Changes in the choroidal thickness following intravitreal bevacizumab injection in chronic central serous chorioretinopathy","volume":"11","author":"Chung","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ophtha.2024.09.003_bib29","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajo.2011.04.008","article-title":"A\u00a0randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy","volume":"152","author":"Bae","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib30","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2013.09.024","article-title":"Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial","volume":"121","author":"Bae","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.09.003_bib31","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/ph13110336","article-title":"Oral treatment of central serous chorioretinopathy patients using propranolol tablets","volume":"13","author":"Chen","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ophtha.2024.09.003_bib32","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/bjophthalmol-2017-311096","article-title":"Spironolactone versus observation in the treatment of acute central serous chorioretinopathy","volume":"102","author":"Sun","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.09.003_bib33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","article-title":"Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): A randomised, double-blind, placebo-controlled trial","volume":"395","author":"Lotery","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2024.09.003_bib34","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10792-016-0377-2","article-title":"Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy","volume":"37","author":"Pichi","year":"2017","journal-title":"Int Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024005529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024005529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T13:51:40Z","timestamp":1740059500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642024005529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0161642024005529"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.09.003","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapies for Central Serous Chorioretinopathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}